Acute and Chronic Anal Fissure: The Role of a New Multitarget Ointment

Giani I, Cioppa T, Caminati F, Linari C, Dreoni P, Rossi G, Bettazzi F, Aprile A, Grassi S, Pede A and Elbetti C

SOSD Proctologia, Azienda USL Toscana Centro, Italy
SOC Chirurgia Generale, Ospedale San Giuseppe-Empoli, Italy
SOC Chirurgia, Ospedale Santa Maria Nuova-Firenze, Italy
SOC Chirurgia Generale, Ospedale Santo Stefano-Prato, Italy
Professional Nurses, USL Toscana Centro, Italy

^*Correspondance to: Caminati Filippo 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction: Anal fissures are an extremely common disease with a severe impact on patients’ quality of life. The main goal of anal fissure treatment is rapid pain relief and long-lasting healing. Recently, various local ointments have been proposed in the treatment of anal fissure. The aim of this study is to evaluate the efficacy of a new multitarget ointment consisting of 4 main active ingredients (Dermonectin, Argirelox, SymSitive and SynCalmin).
Methods: In this observational study the evaluated patients were divided into two groups: Acute and chronic fissures. Patients were instructed to apply the new multitarget ointment every 8 h for 1 month. The first endpoint was the rapid reduction of maximum anal pain intensity and the stabilization of the results in the follow-up. The secondary endpoints were the reduction in bleeding, mean pain intensity, maximum pain duration and relief of specific symptoms. Patient satisfaction was recorded. The number of patients healed was recorded, according to a published re-epithelization score.
Results: During the 9-month observational period, 103 of the 109 patients completed the treatment period. The maximum anal pain intensity at baseline was 7.99 while after 1 month, it was 3.33. Complete resolution of bleeding was achieved in 95% of cases after 1 week. The mean anal pain intensity at baseline (5.6) significantly reduced at 1 month (1.9). Significant reduction of maximum pain duration was recorded. The mean patient satisfaction rate was 8.2 (0-10). At 1 month no patients had deep fissures, 19 patients had a superficial fissure, 38 presented partial re-epithelization and 46 complete healing.
Discussion: In recent years, the focus has shifted to creams for local use, developed with the aim of interrupting the vicious circle underlying the pathophysiology of the fissure. Our study underlined the safety and efficacy of this multitarget ointment and its impact on different types of anal fissure. Its key components achieved all their objectives: Dermonectin promoted the healing process; Argirelox reduced anal hypertonus, promoting healing and reducing pain; SymSitive reduced pain and burning; and SynCalmin acted on the inflammatory process. The synergy of these four active ingredients was therefore a winner.

Keywords:

#

Cite the Article:

Giani I, Cioppa T, Caminati F, Linari C, Dreoni P, Rossi G, et al. Acute and Chronic Anal Fissure: The Role of a New Multitarget Ointment. World J Surg Surgical Res. 2023; 6: 1506..